Clinical trials: Neoplasm of Breast (Disorder)
Breast Cancer
International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study
BREAKOUT -International Breast Cancer Biomarker, Standard of Care and Real World Outcomes Study BREAKOUT is a prospective cross-sectional cohort study of human epidermal growth factor receptor 2 negative metastatic breast cancer…
- Trial name
- BREAKOUT (NCT03078036)
- Testing
- Germline BRCA Test (blood), FoundationOne Dx Genomic Profile (archival Tumour Specimen), Follow-up
- Where
- 98 sites in United States, Australia and 13 more
- Volunteers
- 873 people
- Sponsor
- AstraZeneca
Breast Cancer
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.
- Trial name
- NCT07062965
- Testing
- PF-07248144, Fulvestrant, Everolimus
- Where
- 433 sites in United States, Argentina and 29 more
- Volunteers
- 400 people
- Sponsor
- Pfizer
Triple Negative Breast Cancer
Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC
The purpose of this study is to determine the activity of ENMD-2076 as defined by the clinical benefit rate when patients with previously treated locally advanced or metastatic triple negative breast cancer are treated with daily…
- Trial name
- NCT01639248
- Testing
- ENMD-2076
- Where
- 3 sites in United States, China
- Volunteers
- 41 people
- Sponsor
- CASI pharmaceuticals, Inc.
Breast Cancer, Breast Lesions
Breast Ultrasound Image Reviewed With Assistance of Deep Learning Algorithms
This study evaluates a second review of ultrasound images of breast lesions using an interactive "deep learning" (or artificial intelligence) program developed by Samsung Medical Imaging, to see if this artificial intelligence…
- Conditions
- Breast Cancer, Breast Lesions, Breast Mass
- Trial name
- NCT03706534
- Testing
- Ultrasound Image review with CADe, Ultrasound Image review with CADx, Ultrasound Image manual review
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Samsung Medison
HR+ HER2- Breast Cancer
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants…
- Trial name
- NCT07558733
- Testing
- Serabelisib, Sapanisertib, Fulvestrant
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Faeth Therapeutics
Breast Cancer
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
The purpose of this study is to determine if BMS-690514 + letrozole will be more effective than lapatinib + letrozole in patients who have metastatic hormone receptor positive breast cancer after developing progressive disease…
- Trial name
- NCT01068704
- Testing
- BMS-690514, Lapatinib, Letrozole
- Where
- 8 sites in United States, Argentina and 2 more
- Volunteers
- 4 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer Detection, Breast Neoplasm
Molecular Breast Imaging (MBI)-Guided Biopsy
The goal of this pilot clinical trial is to demonstrate supplemental screening MBI (molecular breast imaging) in women with dense breasts.
- Conditions
- Breast Cancer Detection, Breast Neoplasm, Molecular Imaging, Biopsy
- Trial name
- MBI-GB-Pilot (NCT07114679)
- Testing
- Molecular Breast Imaging, MBI-guided biopsy
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Smart Breast Corp.
Solid Tumor, TNBC - Triple-Negative Breast Cancer
PhI to Solid Tumors and PhII to Locally Advanced or mTNBC
PhI Dose Escalation with BOIN design in advanced Solid Tumor with Triple combination therapy to determine MTD and RP2D
- Trial name
- NCT05390710
- Testing
- LAE005 + Afuresertib + Nab-Paclitaxel
- Where
- 5 sites in China
- Volunteers
- 21 people
- Sponsor
- Laekna Limited
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- EXCEED (NCT06238479)
- Testing
- LY4101174
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 490 people
- Sponsor
- Eli Lilly and Company
Advanced Cancer, Metastatic Cancer
A Study of LY3023414 in Participants With Advanced Cancer
The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer.
- Conditions
- Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer
- Trial name
- NCT01655225
- Testing
- LY3023414, Midazolam, Fulvestrant
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 156 people
- Sponsor
- Eli Lilly and Company
HER2 Amplified Breast Cancer
A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib
This study will investigate colon pathology in patients with HER2-positive breast cancer treated with neratinib. Colonoscopy will be performed after eligibility has been confirmed, prior to administration of the first dose of…
- Trial name
- NCT04366713
- Testing
- Neratinib, Capecitabine, Loperamide
- Where
- Portugal
- Volunteers
- 6 people
- Sponsor
- Puma Biotechnology, Inc.
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Breast Neoplasms, Breast Cancer
An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer
This study is intended to evaluate the safety, tolerability, and possible effectiveness of an investigational humanized monoclonal antibody (CAL) to the parathyroid hormone-related protein (PTHrP) when compared to zoledronic acid…
- Conditions
- Breast Neoplasms, Breast Cancer, Metastasis
- Trial name
- NCT00051779
- Testing
- CAL
- Where
- 38 sites in United States
- Sponsor
- Chugai Pharma USA
Breast Cancer
A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer
The progression free survival and efficacy of 250 mg ZD1839 in combination with a fixed dose of fulvestrant 250 mg im once a month will be evaluated in female patients with histologically-confirmed advanced or metastatic, ER…
- Trial name
- NCT00234403
- Testing
- gefitinib and fulvestrant
- Where
- 7 sites in Spain
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Breast Neoplasm
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
The intravenously administered taxane, paclitaxel, is one of the most commonly employed agents for the treatment of both localized and advanced breast cancer.
- Trial name
- NCT01221870
- Testing
- Tesetaxel once every 3 weeks, Tesetaxel once weekly
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Genta Incorporated
Triple Negative Breast Cancer
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with metastatic or unresectable TNBC who have progressed on or after anthracycline-based chemotherapy or who have…
- Trial name
- NCT03175666
- Testing
- avelumab, bevacizumab, capecitabine
- Sponsor
- ImmunityBio, Inc.
Breast Neoplasms
EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients
The purpose of this study is to assess the efficacy, safety and tolerability of a therapy with EndoTAG-1 + paclitaxel in combination and EndoTAG-1 alone as a rescue therapy for patients with relapsed or metastatic triple receptor…
- Trial name
- NCT00448305
- Testing
- EndoTAG-1 + paclitaxel, EndoTAG-1, Paclitaxel
- Where
- 33 sites in Belgium, France and 4 more
- Volunteers
- 143 people
- Sponsor
- MediGene
Breast Cancer
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin in combination with Pertuzumab with or without Toripalimab neoadjuvant therapy in patients with HER2-positive breast cancer.
- Trial name
- NCT06178159
- Testing
- Disitamab Vedotin Injection, Pertuzumab Injection, Toripalimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- RemeGen Co., Ltd.
Breast Cancer
Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.
This is a multi-center, randomized, two-arm study designed to measure the effectiveness of the SELENE system in reducing the number of unaddressed positive margins in breast lumpectomy procedures when used in addition to standard…
- Trial name
- RCT (NCT05113927)
- Testing
- Selene
- Where
- 10 sites in United States
- Volunteers
- 613 people, healthy volunteers welcome
- Sponsor
- Perimeter Medical Imaging
Metastatic Breast Cancer
First Line Therapy for Patients With Metastatic Breast Cancer
The purpose of this study is to determine the toxicity and anti-tumor activity of nab-paclitaxel 100mg/m^2 administered weekly in a 4-week cycle as first line therapy to patients with metastatic breast cancer who received taxanes…
- Trial name
- NCT00456846
- Testing
- ABI-007
- Where
- 14 sites in Canada
- Volunteers
- 123 people
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.